ArticleCancer biology & therapy2013

FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.

Bora Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.